Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Cash from Financing Activities data on file, last reported at -$1.0 million in Q2 2026.

• Quarterly Cash from Financing Activities fell 116.67% year-over-year to -$1.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$401.0 million (up 83.37% YoY) and the FY2025 annual result came in at -$2.2 billion, down 20.1% from the prior year.
• Cash from Financing Activities eased to -$1.0 million in Q2 2026, from $13.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $40.0 million in Q4 2025 to a low of -$1.7 billion in Q1 2025.
• A 5-year average of -$431.1 million and a median of -$439.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 35400.0% — and 2025, when it soared 105.93%.
• Tracing TEVA's Cash from Financing Activities over 5 years: stood at -$711.0 million in 2022, then increased by 18.99% to -$576.0 million in 2023, then fell by 17.01% to -$674.0 million in 2024, then surged by 105.93% to $40.0 million in 2025, then tumbled by 102.5% to -$1.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.0 million (Q2 2026), $13.0 million (Q1 2026), and $40.0 million (Q4 2025), per Business Quant data.